Acadia Pharmaceuticals Inc. (ACAD)

[IanFromSI]

There was no new news in the CNN piece. All information had been submitted to, and, reviewed by, the FDA.

Nuplazid is the only approved tx for PDP.

This disease is degenerative and terminal. Pts die without tx.
With Nuplazid fewer die than giving them nothing or even worse,
an antipsychotic being prescribed off label.

The FDA gets all Adverse Effect reports (which includes deaths).
The FDA reviews all Adverse Effect reports. If all remains consistent with the approval info, they'll say nothing further.

If Nuplazid gets approved for ADP (Alzheiemr's), I'd expect it to have a very significant impact on share price as long as it remains the only approved tx for both PDP and ADP.

If another better drug gets approved for these conditions, then ACAD will not do exceptionally well. Same is true for a CRL rather than approval for ADP.

I took my money off the table in the Mid 30s (shares bought below $10). I'm holding the balance of my shares for now.